Sorry, you need to enable JavaScript to visit this website.

VYNDAQEL® OR VYNDAMAX™ (tafamidis meglumine or tafamidis) Drug Interactions

7. DRUG INTERACTIONS

7.1 BCRP Substrates

Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) following VYNDAQEL 80 mg or VYNDAMAX 61 mg. Dose adjustment may be needed for these substrates.

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Search

Please enter your search term(s) for VYNDAQEL® OR VYNDAMAX™